KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for West Pharmaceutical Services (WST) over the last 8 years, with Q4 2025 value amounting to $7.3 million.

  • West Pharmaceutical Services' Asset Writedowns and Impairment rose 3518.52% to $7.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $11.7 million, marking a year-over-year increase of 6027.4%. This contributed to the annual value of $11.7 million for FY2025, which is 6027.4% up from last year.
  • Per West Pharmaceutical Services' latest filing, its Asset Writedowns and Impairment stood at $7.3 million for Q4 2025, which was up 3518.52% from $300000.0 recorded in Q3 2025.
  • Over the past 5 years, West Pharmaceutical Services' Asset Writedowns and Impairment peaked at $7.3 million during Q4 2025, and registered a low of $200000.0 during Q2 2022.
  • Over the past 4 years, West Pharmaceutical Services' median Asset Writedowns and Impairment value was $1.5 million (recorded in 2023), while the average stood at $2.3 million.
  • As far as peak fluctuations go, West Pharmaceutical Services' Asset Writedowns and Impairment crashed by 8000.0% in 2024, and later soared by 116666.67% in 2025.
  • West Pharmaceutical Services' Asset Writedowns and Impairment (Quarter) stood at $4.6 million in 2022, then tumbled by 41.3% to $2.7 million in 2023, then surged by 100.0% to $5.4 million in 2024, then skyrocketed by 35.19% to $7.3 million in 2025.
  • Its Asset Writedowns and Impairment stands at $7.3 million for Q4 2025, versus $300000.0 for Q3 2025 and $3.8 million for Q2 2025.